Here’s a structured FAQ for researchers investigating PAR2 antibodies in academic contexts, synthesized from peer-reviewed studies and optimized for methodological depth:
Local delivery: Intranasal or intra-articular administration (tested in arthritis models) to bypass systemic exposure limitations .
Bispecific designs: Combine PAR2 inhibition with VEGF/TNF-α blockers to target multi-pathway diseases (e.g., atherosclerosis) .
Molecular docking: Predict binding pockets (e.g., PAR2 antagonist AZ8838 binds a site distinct from the tethered ligand domain) .
Cryo-EM/XR: Resolve antibody-PAR2 complexes to guide affinity maturation (e.g., Fab3949 blocks ligand-receptor engagement) .